Intellectual Property
Feb. 27, 2025
Federal judge overturns $96M patent verdict against organ transplant testing company
A Delaware federal judge has overturned a $96 million jury verdict against Brisbane-based CareDx Inc., ruling that the patent at issue in its dispute with rival Natera Inc. is invalid. The decision, a major victory for Weil Gotshal partner Edward R. Reines, erases the damages award unless Natera successfully appeals.
Attorneys with Weil, Gotshal & Manges LLP have persuaded a federal judge to reverse a $96 million patent infringement jury verdict against a Brisbane genetic testing company.
A Delaware federal jury concluded in January 2024 that two DNA blood tests made by CareDx Inc. to determine whether an organ transplant is being rejected - AlloSure and AlloSeq - infringed the patent of a rival, Natera Inc.
But on Monday, Chief Judge Colm F. Connolly of the District of Delaware ...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In